These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 19502261)

  • 21. In vitro effects of antiphospholipid syndrome-IgG fractions and human monoclonal antiphospholipid IgG antibody on human umbilical vein endothelial cells and monocytes.
    Clemens N; Frauenknecht K; Katzav A; Sommer C; von Landenberg P
    Ann N Y Acad Sci; 2009 Sep; 1173():805-13. PubMed ID: 19758232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complement activation: a novel pathogenic mechanism in the antiphospholipid syndrome.
    Pierangeli SS; Vega-Ostertag M; Liu X; Girardi G
    Ann N Y Acad Sci; 2005 Jun; 1051():413-20. PubMed ID: 16126983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elevated circulating endothelial microparticles and brachial-ankle pulse wave velocity in well-controlled hypertensive patients.
    Wang JM; Su C; Wang Y; Huang YJ; Yang Z; Chen L; Wu F; Xu SY; Tao J
    J Hum Hypertens; 2009 May; 23(5):307-15. PubMed ID: 19037229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platelet-derived microparticles from recurrent miscarriage associated with antiphospholipid antibody syndrome influence behaviours of trophoblast and endothelial cells.
    Zhou Q; Lian Y; Zhang Y; Li L; Li H; Shen D; Zhou Y; Zhang M; Lu Y; Liu J; Xia Y; Wang X
    Mol Hum Reprod; 2019 Aug; 25(8):483-494. PubMed ID: 30953065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new cytofluorimetric approach to evaluate the circulating microparticles in subjects with antiphospholipid antibodies.
    Niccolai E; Squatrito D; Emmi G; Silvestri E; Emmi L; Ciucciarelli L; Ricci F; Manganaro D; Amedei A; Prisco D
    Thromb Res; 2015 Dec; 136(6):1252-8. PubMed ID: 26476741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating microparticles, lupus anticoagulant and recurrent miscarriages.
    Alijotas-Reig J; Palacio-Garcia C; Vilardell-Tarres M
    Eur J Obstet Gynecol Reprod Biol; 2009 Jul; 145(1):22-6. PubMed ID: 19410360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Studies of microparticles in patients with the antiphospholipid syndrome (APS).
    Vikerfors A; Mobarrez F; Bremme K; Holmström M; Ågren A; Eelde A; Bruzelius M; Antovic A; Wallén H; Svenungsson E
    Lupus; 2012 Jun; 21(7):802-5. PubMed ID: 22635239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a thrombin generation test in cultured endothelial cells: Evaluation of the prothrombotic effects of antiphospholipid antibodies.
    Billoir P; Miranda S; Damian L; Richard V; Benhamou Y; Le Cam Duchez V
    Thromb Res; 2018 Sep; 169():87-92. PubMed ID: 30031291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endothelial dysfunction in HIV infection--the role of circulating endothelial cells, microparticles, endothelial progenitor cells and macrophages.
    López M; San Román J; Estrada V; Vispo E; Blanco F; Soriano V
    AIDS Rev; 2012; 14(4):223-30. PubMed ID: 23258297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microparticles, vascular function and hypertension.
    Boulanger CM
    Curr Opin Nephrol Hypertens; 2010 Mar; 19(2):177-80. PubMed ID: 20051854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiphospholipid antibodies: effects on trophoblast and endothelial cells.
    D'Ippolito S; Di Simone N; Di Nicuolo F; Castellani R; Caruso A
    Am J Reprod Immunol; 2007 Aug; 58(2):150-8. PubMed ID: 17631008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tissue factor in the antiphospholipid syndrome.
    Kinev AV; Roubey RA
    Lupus; 2008 Oct; 17(10):952-8. PubMed ID: 18827061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microparticles and type 2 diabetes.
    Leroyer AS; Tedgui A; Boulanger CM
    Diabetes Metab; 2008 Feb; 34 Suppl 1():S27-32. PubMed ID: 18358424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endothelial microparticles: missing link in endothelial dysfunction?
    Yong PJ; Koh CH; Shim WS
    Eur J Prev Cardiol; 2013 Jun; 20(3):496-512. PubMed ID: 22496273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The influence of anti-endothelial/antiphospholipid antibodies on fibrin formation and lysis on endothelial cells.
    Patterson AM; Ford I; Graham A; Booth NA; Greaves M
    Br J Haematol; 2006 May; 133(3):323-30. PubMed ID: 16643435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endothelial cell microparticles and antiphospholipid syndrome: pathologic explanations and diagnostic opportunities.
    Greer IA
    Thromb Haemost; 2004 Apr; 91(4):636-8. PubMed ID: 15101389
    [No Abstract]   [Full Text] [Related]  

  • 37. Prothrombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome.
    Forastiero R; Martinuzzo M
    Lupus; 2008 Oct; 17(10):872-7. PubMed ID: 18827051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microparticles: An Alternative Explanation to the Behavior of Vascular Antiphospholipid Syndrome.
    Álvarez D; Rúa C; Cadavid J ÁP
    Semin Thromb Hemost; 2021 Oct; 47(7):787-799. PubMed ID: 33930895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extracellular Vesicles and Antiphospholipid Syndrome: State-of-the-Art and Future Challenges.
    Štok U; Čučnik S; Sodin-Šemrl S; Žigon P
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiphospholipid antibodies may impair factor XIIa-dependent activation of fibrinolysis in pregnancy: in vitro evidence with human endothelial cells in culture and monoclonal anticardiolipin antibodies.
    Lázaro I; Carmona F; Reverter JC; Cervera R; Tassies D; Balasch J
    Am J Obstet Gynecol; 2009 Jul; 201(1):87.e1-6. PubMed ID: 19427615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.